Drug Trial Radar · NCT07036601
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
276
Planned (sponsor's estimate)
Start
Jan 6, 2025
Primary completion
Feb 13, 2026
Study completion Mar 11, 2026
Sponsor
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.
Conditions
- Overweight or Obese
Interventions
THDBH120 injectionDrug
Participants received THDBH120 by subcutaneous injection.
Placebo of THDBH120 injectionDrug
Participants received placebo by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weightTime frame: Baseline, Week26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Xiangya Hospital of Central South University
Changsha, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.